

Shrinking the Gap Between Sci-Fi and Sci-Fact: Josh Wolfe (Co-Founder of Lux Capital)
63 snips Apr 15, 2025
Josh Wolfe, co-founder of Lux Capital, dives into futuristic innovations like genetically modified pig organs for transplantation and the groundbreaking technology allowing us to 'teleport' smells. He discusses how these advancements can reshape industries and even lead to life-saving medical solutions. Wolfe emphasizes the role of speculative risks in tech investments and shares insights on identifying market trends. Additionally, he explores the fascinating intersection of comic book lore with biotechnology, promising a thrilling glimpse into the future of science.
AI Snips
Chapters
Books
Transcript
Episode notes
Sci-Fi to Sci-Fact Investing
- Josh Wolfe funds ventures like gene-edited organs and digitized smells at Lux Capital.
- His firm backs companies that create the future, bridging science fiction and fact.
Xenotransplantation Breakthrough
- Genetically modified pig kidneys are being transplanted into humans, marking a breakthrough in xenotransplantation.
- eGenesis pioneered this technology, enabling immunocompatible transplants with reduced immunosuppressants.
CRISPR's Role in Xenotransplantation
- CRISPR gene editing enabled the xenotransplantation breakthrough by making pig organs compatible.
- Lux Capital invested heavily in eGenesis after successful surgeries proved the technology.